Healio roundup: Top coverage in breast cancer from ASCO 2022
Click Here to Manage Email Alerts
Healio rounded up the top breast cancer coverage presented and discussed at ASCO Annual Meeting in Chicago.
The top story in breast cancer was a presentation that demonstrated the possibility of safe avoidance of radiotherapy following breast-conserving surgery among older patients with low-grade luminal A breast cancer. According to Timothy Joseph Whelan, MD, FASCO, professor of oncology and Canada research chair in breast cancer research at McMaster University, and colleagues, treatment with only endocrine therapy after breast-conserving surgery may allow for the safe omission of radiation therapy.
Another important presentation from this year’s conference was DESTINY-Breast04 trial, which demonstrated “a new standard of care.” The trial results were presented by Shanu Modi, MD, medical oncologist at Memorial Sloan Kettering Cancer Center, who discussed how trastuzumab deruxtecan significantly lengthened progression-free survival and overall survival among patients with HER2-low metastatic breast cancer.
Read more top stories on breast cancer from ASCO 2022 below:
Lung, breast, bowel cancers dominate ASCO social media conversation among HCPs
ASCO Annual Meeting, held in person for the first time since 2019 due to the COVID-19 pandemic, took place June 3-7 in Chicago.
Creation Healthcare said ASCO — also accessible virtually via live or on-demand sessions — provided a great platform for health care professionals (HCP) to learn about the latest developments in oncology while reconnecting with their peers. Read more.
‘Beautiful, powerful moment’ and Twitter buzz after DESTINY-Breast04 data presented
Eleanora Teplinsky, MD (@drteplinsky). June 5, 2022. Standing ovation for results of DESTINY-Breast04. This will change practice for 50% of patients with metastatic breast cancer. This is why we all went into this field. #bcsm #ASCO22. [Video in original post.] Twitter.
Paolo Tarantino (@PTarantinoMD). June 5, 2022. Standing ovation after the #ASCO22 Plenary presentation of DESTINY-Breast04 by Dr. Shanu Modi. A beautiful, powerful moment, that will remain in the history of breast oncology. Twitter.
So far, Tarantino’s tweet has garnered more than 650 likes and 65 retweets, and here is why. Read more.
Sacituzumab govitecan significantly extends PFS in advanced breast cancer subset
Sacituzumab govitecan significantly extended PFS vs. single-agent chemotherapy among a heavily pretreated subset of patients with advanced breast cancer subset, according to study results presented during ASCO Annual Meeting.
The findings also showed sacituzumab govitecan (Trodelvy, Gilead), an antibody-drug conjugate consisting of an anti-Trop-2 antibody, had a manageable safety profile among the study population. Read more.
Adjuvant chemotherapy plus endocrine therapy fails to increase OS in breast cancer subset
The addition of chemotherapy to endocrine therapy did not extend OS after surgery among older patients with ER-positive, HER2-negative breast cancer with a high tumor genomic grade index.
Researchers presented the results of the Unicancer ASTER 70s trial at ASCO Annual Meeting. Read more.
Continued CDK 4/6 inhibition after breast cancer progression may benefit some patients
Ribociclib extended PFS among patients with hormone receptor-positive, HER2-negative metastatic breast cancer who switched endocrine therapy and received the drug after progression on a CDK 4/6 inhibitor, study results showed.
The findings of the double-blind, randomized phase 2 MAINTAIN trial, presented at ASCO Annual Meeting, demonstrated the potential benefit of continued CDK 4/6 inhibition with hormone therapy for these patients. Read more.